{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,15]],"date-time":"2025-06-15T00:40:05Z","timestamp":1749948005758,"version":"3.41.0"},"reference-count":36,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,5]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Elevated soluble urokinase plasminogen activator receptor (suPAR) has been associated with a poor prognosis in serious infections. The aim of this study was to evaluate the clinical value of suPAR in children with acute coronavirus disease 2019 (COVID-19) or multisystem inflammatory syndrome (MIS-C).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Serum suPAR was measured using the suPARnostic AUTO Flex enzyme-linked immunosorbent assay in hospitalized children with COVID-19, MIS-C, bacterial pneumonia, and healthy controls.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>A total of 211 children with a mean (\u00b1SD) age of 6.9\u2009\u00b1\u20094.96 years were tested; with COVID-19: 59 (28%), MIS-C: 36 (17%), pneumonia: 78 (37%) and healthy controls: 38 (18%). In the acute phase, the levels of suPAR (mean \u00b1 SD) were: MIS-C: 8.11\u2009\u00b1\u20092.80\u2009ng\/mL, COVID-19: 4.91\u2009\u00b1\u20091.90\u2009ng\/mL, pneumonia: 4.25\u2009\u00b1\u20091.44\u2009ng\/mL and controls: 2.09\u2009\u00b1\u20090.47\u2009ng\/mL (<jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.001). Children with acute COVID-19 and a severe or moderate clinical presentation had higher values than those with mild symptoms: 5.79\u2009\u00b1\u20091.58 versus 5.40\u2009\u00b1\u20091.94 versus 3.19\u2009\u00b1\u20090.73\u2009ng\/mL, respectively (<jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.001). In the MIS-C group, children hospitalized in the intensive care unit and in need of mechanical ventilation had higher suPAR than those who were not admitted to an intensive care unit: 9.32\u2009\u00b1\u20093.06 versus 7.13\u2009\u00b1\u20092.19\u2009ng\/mL, respectively (<jats:italic toggle=\"yes\">P<\/jats:italic> = 0.023). In children with COVID-19 or MIS-C, a correlation was detected between suPAR values and length of hospitalization (<jats:italic toggle=\"yes\">r<\/jats:italic>\n                                 <jats:sub>\n                                    s\n                                 <\/jats:sub> = 0.418, <jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.001).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>The findings suggest that suPAR may be a valuable biomarker of disease severity in children with COVID-19 or MIS-C. This could facilitate the identification of children in need of intensive anti-inflammatory treatment, as it has been shown in adults with severe COVID-19.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/inf.0000000000004244","type":"journal-article","created":{"date-parts":[[2024,1,22]],"date-time":"2024-01-22T14:00:32Z","timestamp":1705932032000},"page":"477-482","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["The Soluble Urokinase Plasminogen Activator Receptor as a Severity Biomarker in Children With Acute COVID-19 or Multisystem Inflammatory Syndrome"],"prefix":"10.1097","volume":"43","author":[{"given":"Magdalini","family":"Louka","sequence":"first","affiliation":[{"name":"From the First Department of Pediatrics, Infectious Diseases and Chemotherapy Research Laboratory, Medical School, National and Kapodistrian University of Athens, \u201cAghia Sophia\u201d Children\u2019s Hospital, Athens Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth Barbara","family":"Tatsi","sequence":"additional","affiliation":[{"name":"From the First Department of Pediatrics, Infectious Diseases and Chemotherapy Research Laboratory, Medical School, National and Kapodistrian University of Athens, \u201cAghia Sophia\u201d Children\u2019s Hospital, Athens Greece"},{"name":"University Research Institute of Maternal and Child Health and Precision Medicine, Athens, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sofia","family":"Vassiliu","sequence":"additional","affiliation":[{"name":"From the First Department of Pediatrics, Infectious Diseases and Chemotherapy Research Laboratory, Medical School, National and Kapodistrian University of Athens, \u201cAghia Sophia\u201d Children\u2019s Hospital, Athens Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George","family":"Theoharis","sequence":"additional","affiliation":[{"name":"From the First Department of Pediatrics, Infectious Diseases and Chemotherapy Research Laboratory, Medical School, National and Kapodistrian University of Athens, \u201cAghia Sophia\u201d Children\u2019s Hospital, Athens Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kalliopi","family":"Straka","sequence":"additional","affiliation":[{"name":"Pediatric Intensive Care Unit, \u201cAghia Sophia\u201d Children\u2019s Hospital, Athens, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Filippos","family":"Filippatos","sequence":"additional","affiliation":[{"name":"From the First Department of Pediatrics, Infectious Diseases and Chemotherapy Research Laboratory, Medical School, National and Kapodistrian University of Athens, \u201cAghia Sophia\u201d Children\u2019s Hospital, Athens Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Myrto","family":"Dourdouna","sequence":"additional","affiliation":[{"name":"From the First Department of Pediatrics, Infectious Diseases and Chemotherapy Research Laboratory, Medical School, National and Kapodistrian University of Athens, \u201cAghia Sophia\u201d Children\u2019s Hospital, Athens Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tania","family":"Siahanidou","sequence":"additional","affiliation":[{"name":"Neonatal Unit, First Department of Pediatrics, Medical School, National and Kapodistrian University of Athens, \u201cAghia Sophia\u201d Children\u2019s Hospital, Athens, Greece."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vasiliki","family":"Syriopoulou","sequence":"additional","affiliation":[{"name":"From the First Department of Pediatrics, Infectious Diseases and Chemotherapy Research Laboratory, Medical School, National and Kapodistrian University of Athens, \u201cAghia Sophia\u201d Children\u2019s Hospital, Athens Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Athanasios","family":"Michos","sequence":"additional","affiliation":[{"name":"From the First Department of Pediatrics, Infectious Diseases and Chemotherapy Research Laboratory, Medical School, National and Kapodistrian University of Athens, \u201cAghia Sophia\u201d Children\u2019s Hospital, Athens Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2024,1,22]]},"reference":[{"key":"R2-20250614","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1111\/apa.15270","article-title":"Systematic review of COVID-19 in children shows milder cases and a better prognosis than adults.","volume":"109","author":"Ludvigsson","year":"2020","journal-title":"Acta Paediatr"},{"key":"R3-20250614","first-page":"170","article-title":"COVID-19 in children: heterogeneity within the disease and hypothetical pathogenesis.","volume":"38","author":"Suratannon","year":"2020","journal-title":"Asian Pac J Allergy Immunol"},{"key":"R4-20250614","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.ijid.2020.11.163","article-title":"Severe COVID-19 infection and pediatric comorbidities: a systematic review and meta-analysis.","volume":"103","author":"Tsankov","year":"2021","journal-title":"Int J Infect Dis"},{"key":"R5-20250614","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1136\/postgradmedj-2018-135839","article-title":"SuPAR, an emerging biomarker in kidney and inflammatory diseases.","volume":"94","author":"Hamie","year":"2018","journal-title":"Postgrad Med J"},{"key":"R6-20250614","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1155\/2009\/504294","article-title":"suPAR: the molecular crystal ball.","volume":"27","author":"Thun\u00f8","year":"2009","journal-title":"Dis Markers"},{"key":"R7-20250614","doi-asserted-by":"crossref","first-page":"791716","DOI":"10.3389\/fmed.2021.791716","article-title":"Soluble Urokinase Plasminogen Activator Receptor (suPAR) independently predicts severity and length of hospitalisation in patients with COVID-19.","volume":"8","author":"Enocsson","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"R8-20250614","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1111\/j.1365-2796.2010.02252.x","article-title":"Circulating soluble urokinase plasminogen activator receptor predicts cancer, cardiovascular disease, diabetes and mortality in the general population.","volume":"268","author":"Eugen-Olsen","year":"2010","journal-title":"J Intern Med"},{"key":"R9-20250614","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1038\/s41591-021-01499-z","article-title":"Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial.","volume":"27","author":"Kyriazopoulou","year":"2021","journal-title":"Nat Med"},{"key":"R10-20250614","doi-asserted-by":"crossref","first-page":"e66125","DOI":"10.7554\/eLife.66125","article-title":"An open label trial of anakinra to prevent respiratory failure in covid-19.","volume":"10","author":"Kyriazopoulou","year":"2021","journal-title":"Elife"},{"key":"R12-20250614","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1186\/s13054-020-02897-4","article-title":"Soluble urokinase plasminogen activator receptor (suPAR) as an early predictor of severe respiratory failure in patients with COVID-19 pneumonia.","volume":"24","author":"Rovina","year":"2020","journal-title":"Crit Care"},{"key":"R13-20250614","doi-asserted-by":"crossref","first-page":"2725","DOI":"10.1681\/ASN.2020060829","article-title":"Soluble Urokinase Receptor (SuPAR) in COVID-19\u2013Related AKI.","volume":"31","author":"Azam","year":"2020","journal-title":"J Am Soc Nephrol"},{"key":"R15-20250614","doi-asserted-by":"crossref","first-page":"e2021055765","DOI":"10.1542\/peds.2021-055765","article-title":"Severity of acute COVID-19 in children < 18 years old March 2020 to December 2021.","volume":"149","author":"Forrest","year":"2022","journal-title":"Pediatrics"},{"key":"R17-20250614","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1136\/emermed-2020-210380","article-title":"Predicting outcomes of COVID-19 from admission biomarkers: a prospective UK cohort study.","volume":"38","author":"Arnold","year":"2021","journal-title":"Emerg Med J"},{"key":"R18-20250614","doi-asserted-by":"crossref","first-page":"117727192110346","DOI":"10.1177\/11772719211034685","article-title":"suPAR Cut-offs for risk stratification in patients with symptoms of COVID-19.","volume":"16","author":"Altintas","year":"2021","journal-title":"Biomark Insights"},{"key":"R19-20250614","doi-asserted-by":"crossref","first-page":"98","DOI":"10.24953\/turkjped.2021.4321","article-title":"Soluble urokinase plasminogen activator receptor: a novel biomarker of pediatric community-acquired and hospitalacquired pneumonia.","volume":"64","author":"El-Mekkawy","year":"2022","journal-title":"Turk J Pediatr"},{"key":"R20-20250614","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1089\/ped.2018.0982","article-title":"Levels of soluble urokinase plasminogen activator receptor in pediatric lower respiratory tract infections.","volume":"32","author":"\u00c7itlenbik","year":"2019","journal-title":"Pediatr Allergy Immunol Pulmonol"},{"key":"R21-20250614","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.resp.2014.12.018","article-title":"The role of the soluble urokinase plasminogen activator (suPAR) in children with pneumonia.","volume":"209","author":"Wrotek","year":"2015","journal-title":"Respir Physiol Neurobiol"},{"key":"R22-20250614","doi-asserted-by":"crossref","first-page":"e1079","DOI":"10.1093\/cid\/ciac457","article-title":"Soluble urokinase-type plasminogen activator receptor as a prognostic marker of ugandan children at risk of severe and fatal malaria.","volume":"76","author":"Stefanova","year":"2022","journal-title":"Clin Infect Dis"},{"key":"R23-20250614","doi-asserted-by":"crossref","first-page":"262","DOI":"10.4103\/ijmy.ijmy_52_19","article-title":"Soluble urokinase-type plasminogen activator receptor as a biomarker of treatment response in childhood tuberculosis.","volume":"8","author":"Olivianto","year":"2019","journal-title":"Int J Mycobacteriol"},{"key":"R24-20250614","doi-asserted-by":"crossref","first-page":"100560","DOI":"10.1016\/j.xcrm.2022.100560","article-title":"Development and validation of SCOPE score: a clinical score to predict COVID-19 pneumonia progression to severe respiratory failure.","volume":"3","author":"Giamarellos-Bourboulis","year":"2022","journal-title":"Cell Rep Med"},{"key":"R25-20250614","doi-asserted-by":"crossref","first-page":"e0273202","DOI":"10.1371\/journal.pone.0273202","article-title":"Anakinra in hospitalized COVID-19 patients guided by baseline soluble urokinase plasminogen receptor plasma levels: a real world, retrospective cohort study.","volume":"18","author":"Segala","year":"2023","journal-title":"PLoS One"},{"key":"R26-20250614","first-page":"119","article-title":"Multisystem inflammatory syndrome in children related to SARS-CoV-2.","volume":"23","author":"Esposito","year":"2021","journal-title":"Paediatr Drugs"},{"key":"R27-20250614","doi-asserted-by":"crossref","first-page":"4358","DOI":"10.1002\/jmv.26951","article-title":"The inflammatory markers of multisystem inflammatory syndrome in children (MIS-C) and adolescents associated with COVID-19: A meta-analysis.","volume":"93","author":"Zhao","year":"2021","journal-title":"J Med Virol"},{"key":"R28-20250614","doi-asserted-by":"crossref","first-page":"780641","DOI":"10.3389\/fimmu.2021.780641","article-title":"Soluble urokinase plasminogen activator receptor (suPAR) as a biomarker of systemic chronic inflammation.","volume":"12","author":"Rasmussen","year":"2021","journal-title":"Front Immunol"},{"key":"R29-20250614","doi-asserted-by":"crossref","first-page":"R63","DOI":"10.1186\/cc10037","article-title":"Circulating soluble urokinase plasminogen activator receptor is stably elevated during the first week of treatment in the intensive care unit and predicts mortality in critically ill patients.","volume":"15","author":"Koch","year":"2011","journal-title":"Crit Care"},{"key":"R30-20250614","doi-asserted-by":"crossref","first-page":"91","DOI":"10.4137\/BMI.S19876","article-title":"Risk factors associated with serum levels of the inflammatory biomarker soluble urokinase plasminogen activator receptor in a general population.","volume":"9","author":"Haupt","year":"2014","journal-title":"Biomark Insights"},{"key":"R31-20250614","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.jemermed.2021.03.012","article-title":"Soluble urokinase plasminogen activator receptor as a decision marker for early discharge of patients with COVID-19 symptoms in the emergency department.","volume":"61","author":"Stauning","year":"2021","journal-title":"J Emerg Med"},{"key":"R32-20250614","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1093\/icvts\/ivaa239","article-title":"Can soluble urokinase plasminogen receptor predict outcomes after cardiac surgery?","volume":"32","author":"Schultz-Swarthfigure","year":"2021","journal-title":"Interact Cardiovasc Thorac Surg"},{"key":"R33-20250614","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40124-021-00259-4","article-title":"Treatment of MIS-C in children and adolescents.","volume":"10","author":"Mahmoud","year":"2022","journal-title":"Curr Pediatr Rep"},{"key":"R34-20250614","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s12519-021-00499-w","article-title":"Clinical practice guidelines in multisystem inflammatory syndrome (MIS-C) related to COVID-19: a critical review and recommendations.","volume":"18","author":"Algarni","year":"2022","journal-title":"World J Pediatr"},{"key":"R35-20250614","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/S2352-4642(23)00020-2","article-title":"Methylprednisolone versus intravenous immunoglobulins in children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS): an open-label, multicentre, randomised trial.","volume":"7","author":"Welzel","year":"2023","journal-title":"Lancet Child Adolesc Health"},{"key":"R36-20250614","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1093\/jpids\/piaa115","article-title":"Multicenter interim guidance on use of antivirals for children with coronavirus disease 2019\/severe acute respiratory syndrome coronavirus 2.","volume":"10","author":"Chiotos","year":"2021","journal-title":"J Pediatric Infect Dis Soc"},{"key":"R37-20250614","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.3390\/ijerph16061035","article-title":"Plasma soluble urokinase-type plasminogen activator receptor level as a predictor of the severity of community-acquired pneumonia.","volume":"16","author":"Tsai","year":"2019","journal-title":"Int J Environ Res Public Health"},{"key":"R38-20250614","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12979-018-0141-8","article-title":"Healthy lifestyles reduce suPAR and mortality in a Danish general population study.","volume":"16","author":"Haupt","year":"2019","journal-title":"Immun Ageing"},{"key":"R39-20250614","doi-asserted-by":"crossref","first-page":"951","DOI":"10.3109\/00365521.2012.699549","article-title":"Soluble urokinase plasminogen activator receptor suPAR as a marker for inflammation in pediatric inflammatory bowel disease.","volume":"47","author":"Kolho","year":"2012","journal-title":"Scand J Gastroenterol"},{"key":"R40-20250614","doi-asserted-by":"crossref","first-page":"e0146678","DOI":"10.1371\/journal.pone.0146678","article-title":"Effects of prednisolone on disease progression in antiretroviral-untreated HIV infection: a 2-year randomized, double-blind placebo-controlled clinical trial.","volume":"11","author":"Kasang","year":"2016","journal-title":"PLoS One"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000004244","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,15]],"date-time":"2025-06-15T00:00:21Z","timestamp":1749945621000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000004244"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,22]]},"references-count":36,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000004244","relation":{},"ISSN":["0891-3668"],"issn-type":[{"type":"print","value":"0891-3668"}],"subject":[],"published":{"date-parts":[[2024,1,22]]}}}